Impact of initial severity and progression pattern of new-onset diabetes on pancreatic cancer risk: a 15-year longitudinal nationwide cohort study.

Within the same baseline treatment-intensity category, individuals with rapid escalation within 6 months had a higher risk of pancreatic cancer than those with stable or decreased treatment intensity.

In some comparisons between groups with different baseline treatment intensities, the risk of pancreatic cancer was higher with less intensive baseline therapy but subsequent intensification than with more intensive baseline therapy without progression.